

## APPENDIX 1. Search strategy.

Ovid MEDLINE® and Epub Ahead of Print, In-Process, In-Data-Review, and Other Non-Indexed Citations and Daily <1946 to March 18, 2021>

- 1 (Xospata or gilteritinib).mp.
- 2 1254053-84-3.rn.
- 3 or/1-2 [Xospata]
- 4 drug development/ or exp drug approval/ or exp drug design/ or drug evaluation/ or drug evaluation, preclinical/ or drug repositioning/
- 5 Drug Discovery/
- 6 Drug Costs/
- 7 legislation, drug/ or “drug and narcotic control”/ or drug approval/ or drug recalls/ or safety-based drug withdrawals/
- 8 product surveillance, postmarketing/ or adverse drug reaction reporting systems/ or clinical trials, phase iv as topic/ or pharmacovigilance/ or prescription drug monitoring programs/
- 9 Precision Medicine/
- 10 exp “Drug-Related Side Effects and Adverse Reactions”/
- 11 ((drug\$ or pharm\$) adj3 (lifecycle\$ or life cycle\$)).tw,kf.
- 12 (precision adj (medicine or pharm\$)).tw,kf.
- 13 pharmacovigilan\$.tw,kf.
- 14 ((drug\$ or pharm\$) adj2 (approv\$ or cost\$ or develop\$ or design\$ or discover\$ or disposal\$ or evaluat\$ or industr\$ or legislat\$ or manufacture\$ or market\$ or registrat\$ or regulat\$ or recall\$ or reposition\$ or re-position\$ or research\$ or policy or policies or service\$)).tw,kf.
- 15 or/4-14 [Drug Lifecycle]
- 16 3 and 15 [Xospata and Drug Lifecycle]
- 17 clinical trials as topic/ or clinical trials, phase i as topic/ or clinical trials, phase ii as topic/ or clinical trials, phase iii as topic/ or clinical trials, phase iv as topic/ or controlled clinical trials as topic/ or randomized controlled trials as topic/ or early termination of clinical trials as topic/ or multicenter studies as topic/
- 18 Patient Selection/
- 19 Research Subjects/
- 20 (trial\* adj5 topic).tw,kf.
- 21 ((data adj1 safety adj1 monitor\* boards\*) or data monitor\* committee\*).tw,kf.
- 22 (study design adj3 framework).tw,kf.
- 23 (meta-research\* or metaresearch\*).tw,kf.
- 24 (bibliometric adj3 analys\*).tw,kf.
- 25 (under report\* or underreport\*).tw,kf.
- 26 or/17-25 [Clinical Trials as Topic]
- 27 3 and 26 [Xospata and Clinical Trials]
- 28 exp Gender Identity/
- 29 Sex Factors/
- 30 Sex Characteristics/
- 31 Sexism/
- 32 Women/
- 33 Pregnant Women/
- 34 ((sex adj5 biological variable\$) or (sex adj3 variable)).tw,kf.
- 35 (sex adj2 gender adj3 based).tw,kf.
- 36 (SABV\$ or SGBA\$).tw,kf.
- 37 (gender adj2 (main stream\$ or mainstream\$)).tw,kf.
- 38 ((sex\$ or gender\$) adj3 (analy\$ or aspect\$ or based or bias\$ or characteristic\$ or comparison\$ or determinant\$ or differen\$ or dimorphism\$ or di-morphism\$ or disparit\$ or distribut\* or equalit\$ or equity or factor\$ or identit\$ or inequit\$ or inequalit\$ or informed\$ or institutional\$ or integrated or interaction\* or issue\$ or medicine or minorit\* or norm or norms or related or responsiv\$ or role\$ or specific\$ or transform\$)).tw,kf.
- 39 pregnant wom?n.ti.
- 40 or/28-39 [Sex and Gender Concept]
- 41 3 and 40 [Xospata and Sex]
- 42 16 or 27 or 41

Appendix to: Maximos M, Brabete A, Lê ML, Greaves L. Considering sex and gender in therapeutics throughout the product life cycle: a narrative review and case study of gilteritinib. *Can J Hosp Pharm.* 2023;76(3):239-45.